QIAGEN Solid Tumor Summit

The QIAGEN Solid Tumor Summit (June 29 and 30, 2021) will bring together global oncology experts to discuss their experience and insights in solid tumor research and diagnostic testing. Over two days, our speakers will address many of the challenges encountered in this complex field and share their knowledge about how to improve efficiency, save time and costs, relevant clinical research and ultimately, improve patient care.

The event is free to attend and will provide a unique experience for anyone involved in the field of solid tumor management.
Day 1: June 29, 2021

Presentation: Comparing MLPA and NGS workflows for the pathologic identification of gliomas in clinical research
Speaker: Dr. Michela Bulfoni, Istituto di Anatomia Patologica (ASUFC), Dipartimento di area Medica (DAME), Udine, Italy

Expert panel: Comprehensive genomic profiling or targeted NGS panels - a place for both?
Speakers: Dr. Andrea Ferreira-Gonzalez, Dr. Ravindra Kolhe, Dr. Pauline Rehal and Dr. Peter Wild
Moderator: Dr. Davide Manissero

Presentation: Analysis of clinical samples using the QIAseq Pan-cancer Multimodal Panel and QCI Interpret One for QIAseq
Speaker: Dr. Mattia Schmid, UniLabs, FAMH génétique médicale, Lausanne, Switzerland 

Presentation: Single- and multi-gene technology: making the most of your precious samples
Speaker: Dr. Christopher Corless, School of Medicine, Oregon Health & Science University and Knight Diagnostic Laboratories, Oregon, USA

Day 2: June 30, 2021

Presentation: HRR and HRD: The importance of DNA damage repair
Speakers: Dr. Vikas Gupta, QIAGEN and German HRD Consortium

Presentation: Advances in QIAseq chemistry: Accelerate your NGS workflows
Speaker: Krishna Amin, Global Product Manager NGS, QIAGEN

Presentation: The importance of a simple NGS workflow and interpretation support software in the implementation of CGP
Speaker: Dr. Nicola Normanno, INT Fondazione Pascale, Naples, Italy

Poster competition: Prizegiving ceremony

  • Michela Bulfoni
    Dr. Michela Bulfoni is a biologist and researcher at the Institute of Surgical Pathology, University Hospital of Udine, Italy. She specializes in translational research and precision medicine focused on the integration of circulating biomarkers in clinical practice. Her areas of interest include comprehension and molecular characterization of human cancers in order to contribute to the development of new approaches to prevention and treatment.
    Dr. Michela Bulfoni
  • Andrea Ferreira-Gonzalez

    Dr. Andrea Ferreira-Gonzalez is the Chair of the Division of Molecular Diagnostics and Director of the Molecular Diagnostics Laboratory, in the Department of Pathology at the Virginia Commonwealth University Health System, USA. Dr. Ferreira-Gonzalez has been active in the field of molecular diagnostics for 25 years and has been recognized internationally for her work.

    She is a consultant for the FDA’s Clinical Genetics Panel of the Medical Devices Advisory Committee, Center for Devices and Radiological Health. She served in the HHS Advisory Committee on Genetics, Health and Society (SACGHS) and as a member of HHS Clinical Laboratory Improvement Advisory Committee. She has been involved in the development of clinical guidelines with the Clinical Laboratory Standard Institute and Association for Molecular Pathology (AMP) and was previously AMP President.

    Dr. Andrea Ferreira-Gonzalez
  • Ravindra Kolhe

    Dr. Ravindra Kolhe is a Vice-Chairman and Chief of Section of Molecular and Genetic Pathology in the Department of Pathology at Augusta University in Georgia, USA, where he teaches, conducts research and serves as the CLIA laboratory director of the Georgia Esoteric & Molecular Laboratory and the medical director of the Cytogenetics Laboratory. 

    As a molecular and genetic pathologist, Dr. Kolhe is focused on the molecular and cytogenetic evaluation of patient samples as part of a multi-disciplinary clinical team treating patients in a personalized and precision medicine model. As a breast pathologist, he provides expert opinions for the breast multidisciplinary tumor boards, consultations, and second opinions to difficult cases of breast cancer referred to the Georgia Cancer Center.

    Dr. Ravindra Kolhe
  • Pauline Rehal
    After completing a PhD in Immunology at the University of Birmingham, UK, Dr. Pauline Rehal trained as clinical scientist in molecular genetics. Following this, she was invited to become laboratory manager of the Familial Cancer Research Laboratory at the Ontario Cancer Institute in Toronto, Canada. After returning to the UK, she joined the West Midlands Regional Genetics Laboratory in Birmingham. Dr. Rehal has experience of genomic testing across a wide range of areas including rare disease, prenatal and cancer predisposition testing. For the last 10 years, her work has focused on acquired cancer and her primary role is to oversee the delivery of tumor profiling services for clinical referrals and national trials.
    Dr. Pauline Rehal
  • Peter Wild

    Prof. Dr. Peter J. Wild, is the Director of the Dr. Senckenberg Institute of Pathology in Frankfurt am Main, Germany. After completing medical school in 2001, he trained as a resident in pathology and completed a postgraduate course in medical biometrics at the University of Heidelberg, Germany.

    His clinico-pathological focus is on molecular pathology and uropathology. In September 2012, Prof. Wild became Assistant Professor (tenure track) for Systems Pathology and in 2016 Associate Professor for Systems Pathology at the University Hospital Zurich, Switzerland. In this function, Prof. Wild established and directed the High-Throughput Genomics and Proteomics Laboratory. In 2018, he cofounded the Wildlab (University Hospital Frankfurt MVZ GmbH) for clinical, digital and molecular pathology, together with the University Hospital Frankfurt. Since 2019, he is a senior fellow at the Frankfurt Institute for Advanced Studies (FIAS).

    Prof. Dr. Peter J. Wild
  • Davide Manissero
    Dr. Davide Manissero is Chief Medical Officer – Infection and Immune Diagnostics, QIAGEN, and Honorary Senior Lecturer in Public Health at University College London. His experience spans from diagnostics to drug development and he has held senior public health positions at the WHO and European CDC.
    Dr. Davide Manissero
  • Christopher Corless

    Dr. Christopher Corless is Professor of Pathology at the School of Medicine, Oregon Health & Science University (OHSU) and Chief Medical Officer at Knight Diagnostic Laboratories, Oregon, USA.

    Dr. Corless oversees the development of novel molecular and proteomic tests for solid tumors and his interests include the role of oncogenic mutations in GI stromal tumors, melanomas, and other solid tumors and the development and application of new molecular diagnostic assays for use in research and clinical trials.

    Dr. Christopher Corless
  • Vikas Gupta

    Dr. Vikas Gupta is Associate director, Global Bioinformatics and Software Development lead at QIAGEN Aarhus, Denmark. He completed his undergraduate education in Biotechnology in 2010 from IIT Guwahati, India, followed by master’s and PhD degrees focusing on NGS bioinformatics.

    He joined QIAGEN in 2015 as a Bioinformatician. Currently, he leads Bioinformatics and Software development projects with a major contributor to bioinformatics and algorithm development for RUO and IVD software.

    Dr. Vikas Gupta
  • Krishna Amin

    Krishna Amin completed her undergraduate studies in Biochemistry from the University of Maryland, USA in 2011. She joined QIAGEN in 2011 as a Scientific Associate in the Genomics Services lab.

    She received her PMP certification and moved into a project management role in 2018, developing custom NGS solutions and managing strategic alliances. She has worked with various technology development groups concerning qPCR and next-generation sequencing (NGS) technologies. Currently, Krishna is a Global Product Manager for QIAseq Targeted and Enterprise Genomics.

    Krishna Amin
  • Nicola Normanno

    Dr. Nicola Normanno is Director of the Cell Biology and Biotherapy Unit of INT Fondazione ‘G. Pascale’ and has been the Chairman of the Translational Research Department there since 2006. Dr. Normanno leads a research group involved in both preclinical and clinical studies, with particular interest in the identification of biomarkers associated with sensitivity/resistance to target-based agents in clinical development.

    Dr. Normanno’s group was one of the first to use NGS-based techniques for biomarker discovery in clinical trials in lung and colon carcinoma. His group has also a relevant expertise in liquid biopsy. He is also involved in clinical diagnostics and in the organization of national and international external quality assessment (EQA) schemes in molecular pathology. Dr Normanno is a member of many national and international cancer research associations and he is President of the International Quality Network for Pathology (IQN Path) and President of the Italian Cancer Society (SIC).

    Dr. Nicola Normanno
  • Dr. Michela Bulfoni
    Michela Bulfoni
  • Dr. Andrea Ferreira-Gonzalez
    Andrea Ferreira-Gonzalez
  • Dr. Ravindra Kolhe
    Ravindra Kolhe
  • Dr. Pauline Rehal
    Pauline Rehal
  • Prof. Dr. Peter J. Wild
    Peter Wild
  • Dr. Davide Manissero
    Davide Manissero
  • Dr. Christopher Corless
    Christopher Corless
  • Dr. Vikas Gupta
    Vikas Gupta
  • Krishna Amin
    Krishna Amin
  • Dr. Nicola Normanno
    Nicola Normanno
icon-contact
Need some help?
Contact our events team with any questions about the summit
For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services or your local distributor.
X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm